YTHDF2 and invasive breast carcinoma: To determine whether our findings from LFS-derived astrocytes could be translated to human primary tumors with somatic p53 mutations, we next comprehensively analyzed the association between p53 mutation status and YTHDF2 expression using TCGA databases for 4 cancer types (low grade glioma (LGG), GBM, breast invasive carcinoma (BRCA), and rectal adenocarcinoma (READ)) characterized by high p53 mutation rates.